Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

fluorine F 18 PSMA-1007

A radioconjugate containing the human prostate-specific membrane antigen (PSMA)-targeting ligand, PSMA-1007, labeled with the radioisotope fluorine F 18, with potential imaging activity using positron emission tomography/computed tomography (PET/CT). Upon administration of fluorine F 18 PSMA-1007, the PSMA-1007 moiety targets and binds to PSMA-expressing tumor cells. This allows for visualization of PSMA-expressing cells upon imaging. PSMA, a tumor-associated antigen (TAA) and type II transmembrane protein, is expressed on the membrane of prostatic epithelial cells and strongly overexpressed in prostate cancer (PCa) cells, with its level rising with increasing tumor differentiation and in hormone-refractory cancers.
Synonym:[18F]-PSMA-1007
18FPSMA-1007
fluorine-18 PSMA-1007
PSMA-1007 F-18
Abbreviation:18F-PSMA-1007
F-18-PSMA-1007
Search NCI's Drug Dictionary